Back to top
more

Kenvue Inc. (KVUE)

(Delayed Data from NYSE)

$18.69 USD

18.69
11,484,639

+0.44 (2.41%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $18.70 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 17% (208 out of 251)

Industry: Consumer Products - Staples

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kinjel Shah headshot

How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

by Kinjel Shah

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

Kinjel Shah headshot

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

by Kinjel Shah

J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.

Kinjel Shah headshot

J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Kinjel Shah

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Kinjel Shah headshot

J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

by Kinjel Shah

A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.

Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Stock Market News for May 8, 2024

by Zacks Equity Research

Wall Street ended mixed on Tuesday as investors eagerly awaited signals from the Federal Reserve regarding potential interest rate cuts.

Why Kenvue (KVUE) Could Beat Earnings Estimates Again

by Zacks Equity Research

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

These 2 Consumer Staples Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Key Takeaways From JNJ's (JNJ) Q4 Earnings Presentation

by Zacks Equity Research

J&J's (JNJ) Innovative Medicines as well as MedTech units outperform expectations in the fourth quarter. Here we discuss some highlights of its performance in the fourth quarter.

J&J's (JNJ) Q4 Earnings Beat, Darzalex, Stelara Drive Sales

by Zacks Equity Research

J&J (JNJ) beats estimates for fourth-quarter earnings and sales. Sales of several key drugs like Darzalex, Stelara and Tremfya beat estimates.

J&J (JNJ) Gears Up to Report Q4 Earnings: What's in Store?

by Zacks Equity Research

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Company News for Dec 20, 2023

by Zacks Equity Research

Companies in The News Are: BA, DLAKY, KVUE, INTC, SHEL

J&J (JNJ) Announces 2024 and Long-Term Financial Outlook

by Zacks Equity Research

J&J (JNJ) expects operational sales growth in the range of 5-6% in 2024, driven by both its Innovative Medicine and MedTech divisions.

Sweta Killa headshot

JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus

by Sweta Killa

The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.

J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off

by Zacks Equity Research

J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.

J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation

by Zacks Equity Research

With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.

J&J (JNJ) to Keep 9.5% Stake in Kenvue Post Share Exchange

by Zacks Equity Research

J&J's (JNJ) offer to exchange its shares for the shares of Kenvue, its recently-separated consumer healthcare business, gets oversubscribed. The exchange ratio is 8.0324 for every share of J&J.

Here's Why it is a Good Time to Buy J&J's (JNJ) Stock Now

by Zacks Equity Research

J&J's (JNJ) Pharma sales are being driven by key drugs like Darzalex and new products. J&J's Pharma and MedTech units are likely to continue to drive sales growth in 2023.

Factors to Note Ahead of Hain Celestial's (HAIN) Q4 Earnings

by Zacks Equity Research

Hain Celestial's (HAIN) fourth-quarter fiscal 2023 performance is likely to reflect the adverse impact of weakness in the North America segment and a high inflationary environment.

Down -7.52% in 4 Weeks, Here's Why You Should You Buy the Dip in Kenvue (KVUE)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Kenvue (KVUE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Sweta Killa headshot

ETFs to Bet on the Successful Debut of Kenvue

by Sweta Killa

Kenvue is the world's largest pure-play consumer health company by revenue, and makes well-known products, including Tylenol, Neutrogena, Listerine, Johnson¿¿¿s', Band-Aid, Aveeno, Zyrtec and Nicorette.